Ginkgo Bioworks Holdings Inc vs Hormel Foods Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Hormel Foods Corp trades at $19.19 (market cap $10.69B). The key difference: Hormel Foods Corp is far larger — about 14× Ginkgo Bioworks Holdings Inc's market cap, and Hormel Foods Corp pays a 6.02% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Hormel Foods Corp for 99 Days on average.
| DNA | HRL | |
|---|---|---|
Market Cap | $763.64M | $10.69B |
Volume | 3,204,177 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $26.50 |
52-Week Low | $5.48 | $19.42 |
Typical Hold Time | 7 Days | 99 Days |
Enterprise Value | $865.59M | $12.67B |
Dividend Yield | — | 6.02% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though recent quarters beat EPS estimates. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, while maintaining a 60-year dividend streak. Cash flow trends show improvement from 2025's negative $71M to projected 2026 positive $245M.
HRL presents a value opportunity with 25% upside to consensus target of $24.25, supported by dividend stability. However, declining profit margins and elevated valuation multiples pose headwinds. The Brakebush integration execution and consumer spending trends will be critical for reversing earnings pressure amid competitive food markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →